ArticleCureus2025
Increased Incidence of Postoperative Nausea and Vomiting With Remimazolam Compared to Propofol Following Breast Surgery: A Single-Center, Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Postoperative nausea and vomiting (PONV) is a common postoperative complication. This study compared the incidence of PONV between anesthesia management with remimazolam versus propofol in breast surgery patients. Methods This retrospective study included 413 female patients who underwent breast surgery. Patients were divided into the remimazolam group (R group, n=79) and the propofol group (P group, n=334). The primary outcome was the difference in the incidence of PONV within the first two hours (<2h) and between two to 24 hours (2-24h) after surgery. Additionally, the study evaluated risk factors for PONV and the difference in the rate of postoperative rescue antiemetic use between the two groups. Results Incidence of PONV was significantly higher in the R group compared to the P group at <2h (8 (10.1%) vs. 9 (2.7%), 95% CI of difference 18.5%-40.7%, p=0.007), and at 2-24h (30 (38%) vs. 28 (8.4%), 95% CI of difference 0.6%-14.3%, p<0.001). Logistic regression analysis revealed anesthesia management with remimazolam (odds ratio, OR 7.27, 95% CI 3.34-15.8, p<0.001) was a significant risk factor for PONV 2-24h after surgery. During the first two hours after surgery, use of remimazolam was not a significant risk factor. However, it demonstrated a higher odds ratio than other factors (OR 3.22, 95% CI 0.95-10.9, p=0.06). In an exploratory analysis, the use of flumazenil appeared to increase PONV. Conclusion In breast surgery, management with remimazolam resulted in a higher incidence of PONV compared to propofol 2-24h postoperatively. Use of flumazenil may also have an influence on PONV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.